1. A compound of formula I,
wherein:
R is hydrogen, (C1-C16)-alkyl, (C1-C5)-alkyloxy, (C1-C5)-alkylthio, (C1-C5)-alkylamino, di-(C2-C8)-alkylamino, (C0-C4)-alkylene-(C6-C10)-aryl, (C0-C4)-alkylene-(C5-C12)-heteroaryl, (C0-C4)-alkylene-(C3-C12)-heterocyclyl, (C0-C4)-alkylene-(C3-C12)-cycloalkyl, or a bicyclic (C8-C14) ring system,
wherein the aryl, heteroaryl, heterocyclyl, cycloalkyl or bicyclic (C8-C14) ring system may be mono- or polysubstituted by halogen, (C1-C6)-alkyl, (C1-C3)-alkyloxy, hydroxyl, (C1-C6)-alkylmercapto, amino, (C1-C6)-alkylamino, di-(C2-C12)-alkylamino, mono-(C1-C6)-alkylamino-carbonyl, di-(C2-C8)-alkylaminocarbonyl, (C1-C6)-alkoxycarbonyl, (C1-C6)-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy, (C1-C6)-alkylsulfonyl or aminosulfonyl;
R1 is hydrogen, (C1-C10-alkyl, (C1-C10)-alkyloxy, amino, mono-(C1-C10)-alkylamino, or di-(C2-C12)-alkylamino,
Wherein the alkyl may be substituted by halogen, (C1-C6)-alkyl, (C1-C3)-alkyloxy, hydroxyl, (C1-C6)-alkylmercapto, amino, (C1-C6)-alkylamino, di-(C2-C12)-alkylamino, \u2014(C6-C10)-aryl, \u2014(C5-C12)-heteroaryl, \u2014(C3-C12)-heterocyclyl or \u2014(C3-C12)-cycloalkyl,
Wherein the aryl, heteroaryl, heterocyclyl or cycloalkyl may be mono- or polysubstituted by halogen, (C1-C6)-alkyl, (C1-C3)-alkyloxy, hydroxyl, (C1-C6)-alkylmercapto, amino, (C1-C6)-alkylamino, or di-(C2-C12)-alkylamino;
R2 is hydrogen, (C1-C16)-alkyl, or (C0-C4)-alkylene-(C6-C10)-aryl;
R3 is hydrogen, (C1-C6)-alkyl, (C1-C3)-alkyloxy, hydroxyl, (C1-C6)-alkylmercapto, amino, (C1-C6)-alkylamino, di-(C2-C12)-alkylamino, cyano, (C1-C6)-alkylcarbonyl, halogen, trifluoromethyl, trifluoromethyloxy, (C1-C6)-alkylsulfonyl, or aminosulfonyl;
A is O, S, N(R2), C(R3), C(R3)=C(R3), NH\u2550C(R3), C(R3)=NH, or NH\u2550NH;
B is C(R3), or N;
D is C(R3), or N;
provided that at least one of A, B and D must be nitrogen;
n is 1 or 2;
L is a bond, \u2014C(\u2550O)\u2014, \u2014C(\u2550S)\u2014, \u2014C(\u2550O)\u2014N(R2)-, \u2014C(\u2550O)\u2014O\u2014, \u2014S(O)0-2\u2014, \u2014S(O)0-2\u2014N(R2)-, or a mono- or bicyclic ring system in which one or more ring members may be N(R3), O, S or \u2014C(\u2550O)\u2014; and
M is \u2014C(\u2550O)\u2014N(R2)-, \u2014N(R2)-C(\u2550O)\u2014, \u2014S(O)0-2\u2014, \u2014S(O)0-2\u2014N(R2)-, \u2014N(R2)-S(O)0-2\u2014, \u2014C(\u2550O)\u2014O\u2014, or \u2014O\u2014C(\u2550O)\u2014;
or a physiologically compatible salt thereof.
2. The compound according to claim 1, wherein
A is O, S, N(R2), C(R3), or C(R3)=C(R3);
or a physiologically compatible salt thereof.
3. The compound according to claim 1, wherein
n is 1;
R1 is (C1-C10-alkyl, (C1-C10)-alkyloxy, amino, mono-(C1-C10)-alkylamino, or di-(C2-C12)-alkylamino,
Wherein the alkyl may be substituted by halogen, (C1-C6)-alkyl, (C1-C3)-alkyloxy, hydroxyl, (C1-C6)-alkylmercapto, amino, (C1-C6)-alkylamino, di-(C2-C12)-alkylamino, \u2014(C6-C10)-aryl, \u2014(C5-C12)-heteroaryl, \u2014(C3-C12)-heterocyclyl or \u2014(C3-C12)-cycloalkyl,
Wherein the aryl, heteroaryl, heterocyclyl or cycloalkyl may be mono- or polysubstituted by halogen, (C1-C6)-alkyl, (C1-C3)-alkyloxy, hydroxyl, (C1-C6)-alkylmercapto, amino, (C1-C6)-alkylamino, or di-(C2-C12)-alkylamino;
A is O, S, N(R2), C(R3), or C(R3)=C(R3); and
M is \u2014C(\u2550O)\u2014N(R2)-, \u2014N(R2)-C(\u2550O)\u2014, \u2014S(O)0-2\u2014, \u2014S(O)0-2\u2014N(R2)-, \u2014N(R2)-S(O)0-2\u2014, or \u2014O\u2014C(\u2550O)\u2014;
or a physiologically compatible salt thereof.
4. The compound according to claim 1, wherein
n is 1;
R1 is (C1-C10-alkyl, (C1-C10)-alkyloxy, amino, mono-(C1-C10)-alkylamino, or di-(C2-C12)-alkylamino,
Wherein the alkyl may be substituted by halogen, (C1-C6)-alkyl, (C1-C3)-alkyloxy, hydroxyl, (C1-C6)-alkylmercapto, amino, (C1-C6)-alkylamino, di-(C2-C12)-alkylamino, \u2014(C6-C10)-aryl, \u2014(C5-C12)-heteroaryl, \u2014(C3-C12)-heterocyclyl or \u2014(C3-C12)-cycloalkyl,
Wherein the aryl, heteroaryl, heterocyclyl or cycloalkyl may each optionally be mono- or polysubstituted by halogen, (C1-C6)-alkyl, (C1-C3)-alkyloxy, hydroxyl, (C1-C6)-alkylmercapto, amino, (C1-C6)-alkylamino, or di-(C2-C12)-alkylamino;
A is S, or C(R3)=C(R3);
B is C(R3);
D is N; and
M is \u2014C(\u2550O)\u2014N(R2)-, \u2014N(R2)-C(\u2550O)\u2014, \u2014S(O)0-2\u2014, \u2014S(O)0-2\u2014N(R2)-, \u2014N(R2)-S(O)0-2\u2014, or \u2014O\u2014C(\u2550O)\u2014;
or a physiologically compatible salt thereof.
5. The compound according to claim 1, wherein
n is 1;
R is (C1-C16)-alkyl, (C1-C5)-alkyloxy, (C0-C4)-alkylene-(C6-C10)-aryl, or a bicyclic (C8-C14) ring system,
Wherein the aryl or bicyclic (C8-C14) ring system may be mono- or polysubstituted by halogen, (C1-C6)-alkyl, (C1-C3)-alkyloxy, hydroxyl, (C1-C6)-alkylmercapto, amino, (C1-C6)-alkylamino, di-(C2-C12)-alkylamino, mono-(C1-C6)-alkylaminocarbonyl, di-(C2-C8)-alkylaminocarbonyl, (C1-C6)-alkoxycarbonyl, (C1-C6)-alkylcarbonyl, cyano, trifluoromethyl, trifluoromethyloxy, (C1-C6)-alkylsulfonyl or aminosulfonyl;
R1 is (C1-C10-alkyl, (C1-C10)-alkyloxy, amino, mono-(C1-C10)-alkylamino, or di-(C2-C12)-alkylamino,
Wherein the alkyl may be substituted by halogen, (C1-C6)-alkyl, (C1-C3)-alkyloxy, hydroxyl, (C1-C6)-alkylmercapto, amino, (C1-C6)-alkylamino, di-(C2-C12)-alkylamino, \u2014(C6-C10)-aryl, \u2014(C5-C12)-heteroaryl, \u2014(C3-C12)-heterocyclyl or \u2014(C3-C12)-cycloalkyl,
Wherein the aryl, heteroaryl, heterocyclyl or cycloalkyl may each optionally be mono- or polysubstituted by halogen, (C1-C6)-alkyl, (C1-C3)-alkyloxy, hydroxyl, (C1-C6)-alkylmercapto, amino, (C1-C6)-alkylamino, or di-(C2-C12)-alkylamino;
A is S, or C(R3)=C(R3);
B is C(R3);
D is N;
L is a bond, or \u2014C(\u2550O)\u2014; and
M is \u2014C(\u2550O)\u2014N(R2)-, or \u2014O\u2014C(\u2550O)\u2014;
or a physiologically compatible salt thereof.
6. The compound according to claim 1, which is:
Ethyl 2-5-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo3,4-cpyrrol-2-ylthiazole-5-carboxylate;
N-(2-Cyclopropylethyl)-2-5-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo-3,4-cpyrrol-2-ylthiazole-5-carboxamide;
N-(3-Methylbutyl)-2-5-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo3,4-c-pyrrol-2-ylthiazole-5-carboxamide;
N-(cyclopropylmethyl)-2-5-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo3,4-cpyrrol-2-ylthiazole-5-carboxamide;
N-(3-methylbutyl)-2-(5-quinazolin-4-yl-3,4,5,6-tetrahydro-1H-pyrrolo3,4-cpyrrol-2-yl)-thiazole-5-carboxamide;
N-(Cyclopropylmethyl)-2-(5-quinazolin-4-yl-3,4,5,6-tetrahydro-1H-pyrrolo3,4-cpyrrol-2-yl)thiazole-5-carboxamide;
tert-Butyl 5-5-(3-phenylpropylcarbamoyl)thiazol-2-yl-3,4,5,6-tetrahydro-1H-pyrrolo3,4-c-pyrrole-2-carboxylate;
N-(3-Phenylpropyl)-2-(5-quinazolin-4-yl-3,4,5,6-tetrahydro-1H-pyrrolo3,4-cpyrrol-2-yl)-thiazole-5-carboxamide;
N-(3-Phenylpropyl)-2-5-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo3,4-c-pyrrol-2-ylthiazole-5-carboxamide;
N-(3-Methylbutyl)-6-5-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo3,4-c-pyrrol-2-ylnicotinamide;
N-(3-Methylbutyl)-2-5-(2-bromo-5-methoxybenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo3,4-c-pyrrol-2-ylthiazole-5-carboxamide;
N-(3-Phenylpropyl)-2-5-(2-bromo-5-methoxybenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo3,4-c-pyrrol-2-ylthiazole-5-carboxamide;
N-Phenethyl-6-5-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo3,4-cpyrrole-2-ylnicotinamide;
N-(2-Cyclopropylethyl)-6-5-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo-3,4-cpyrrol-2-ylnicotinamide;
N-Thiazol-2-ylmethyl-6-5-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo-3,4-cpyrrol-2-ylnicotinamide;
N-Methyl-N-thiazol-2-ylmethyl-6-5-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo3,4-cpyrrol-2-ylnicotinamide;
N-Cyclopropylmethyl-6-5-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo-3,4-cpyrrol-2-ylnicotinamide;
N-(3-Hydroxypentyl)-6-5-(2-bromo-5-methoxybenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo-3,4-cpyrrol-2-ylpyridazine-3-carboxamide;
N-(2-Cyclopropylethyl)-6-5-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo-3,4-cpyrrol-2-ylpyridazine-3-carboxamide;
N-Thiazol-5-ylmethyl-6-5-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo-3,4-cpyrrol-2-ylnicotinamide;
N-Cyclopentylmethyl-6-5-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo-3,4-cpyrrol-2-ylnicotinamide;
N-(2-Cyclopentylethyl)-6-5-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo-3,4-cpyrrol-2-ylnicotinamide;
N-Thiazol-4-ylmethyl-6-5-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo-3,4-cpyrrol-2-ylnicotinamide; or
N-(2-cyclopropylethyl)-25-(2-trifluoromethylbenzoyl)-3,4,5,6-tetrahydro-1H-pyrrolo3,4-cpyrrol-2-yl-pyrimidine-5-carboxamide;
or a physiologically compatible salt thereof.
7. A pharmaceutical composition comprising the compound according to claim 1 or a physiologically compatible salt thereof, in combination of a pharmacologically compatible carrier.
8. A pharmaceutical composition comprising the compound according to claim 2 or a physiologically compatible salt thereof, in combination of a pharmacologically compatible carrier.
9. A pharmaceutical composition comprising the compound according to claim 3 or a physiologically compatible salt thereof, in combination of a pharmacologically compatible carrier.
10. A pharmaceutical composition comprising the compound according to claim 4 or a physiologically compatible salt thereof, in combination of a pharmacologically compatible carrier.
11. A pharmaceutical composition comprising the compound according to claim 5 or a physiologically compatible salt thereof, in combination of a pharmacologically compatible carrier.
12. A pharmaceutical composition comprising the compound according to claim 6 or a physiologically compatible salt thereof, in combination of a pharmacologically compatible carrier.
13. The pharmaceutical composition according to claim 7, comprising as a further active ingredient selected from the group consisting of one or more antidiabetics, active hypoglycemic ingredients, HMG-CoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha agonist, PPAR gamma agonists, PPAR delta agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, MTP inhibitors, CETP inhibitors, polymeric bile acid adsorbers, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP citrate lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, HM74A receptor agonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones, \u03b1-glucosidase inhibitors, active ingredients which act on the ATP-dependent potassium channel of the beta cells, glycogen phosphorylase inhibitors, glucagon receptor antagonists, activators of glucokinase, inhibitors of gluconeogenesis, inhibitors of fructose 1,6-biphosphatase, modulators of glucose transporter 4, inhibitors of glutamine: fructose-6-phosphate amidotransferase, inhibitors of dipeptidylpeptidase IV, inhibitors of 11-beta-hydroxysteroid dehydrogenase 1, inhibitors of protein tyrosine phosphatase 1B, modulators of the sodium-dependent glucose transporter 1 or 2, modulators of GPR40, inhibitors of hormone-sensitive lipase, inhibitors of acetyl-CoA carboxylase, inhibitors of phosphoenolpyruvate carboxykinase, inhibitors of glycogen synthase kinase-3 beta, inhibitors of protein kinase C beta, endothelin-A receptor antagonists, inhibitors of I kappaB kinase, modulators of the glucocorticoid receptor, CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, \u03b23 agonists, CB1 receptor antagonists, melanocyte-stimulating hormone agonists, CCK agonists, serotonin reuptake inhibitors, mixed serotoninergic and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, decoupling protein 2 or 3 modulators, leptin agonists, DA agonists, lipaseamylase inhibitors, PPAR modulators, RXR modulators, TR-\u03b2-agonists and amphetamines.
14. A method for treating diabetes, metabolic syndrome, insulin resistance, obesity, a cardiovascular disorder, a CNS disorder, schizophrenia, or Alzheimer’s disease, or for reducing lipid, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 1 or a physiologically compatible salt thereof.
15. A method for treating diabetes, metabolic syndrome, insulin resistance, obesity, a cardiovascular disorder, a CNS disorder, schizophrenia, or Alzheimer’s disease, or for reducing lipid, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 2 or a physiologically compatible salt thereof.
16. A method for treating diabetes, metabolic syndrome, insulin resistance, obesity, a cardiovascular disorder, a CNS disorder, schizophrenia, or Alzheimer’s disease, or for reducing lipid, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 3 or a physiologically compatible salt thereof.
17. A method for treating diabetes, metabolic syndrome, insulin resistance, obesity, a cardiovascular disorder, a CNS disorder, schizophrenia, or Alzheimer’s disease, or for reducing lipid, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 4 or a physiologically compatible salt thereof.
18. A method for treating diabetes, metabolic syndrome, insulin resistance, obesity, a cardiovascular disorder, a CNS disorder, schizophrenia, or Alzheimer’s disease, or for reducing lipid, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 5 or a physiologically compatible salt thereof.
19. A method for treating diabetes, metabolic syndrome, insulin resistance, obesity, a cardiovascular disorder, a CNS disorder, schizophrenia, or Alzheimer’s disease, or for reducing lipid, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the compound according to claim 6 or a physiologically compatible salt thereof.
20. A process for preparing a pharmaceutical composition comprising the compound according to claim 1 or a physiologically compatible salt thereof, in combination of a pharmacologically compatible carrier, which comprises mixing the compound according to claim 1 or the physiologically compatible salt thereof, with the pharmacologically compatible carrier and bringing this mixture into a form suitable for administration.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of receiving data in a multiple-input multiple-output (MIMO) communication system, comprising:
obtaining, from a plurality of receive antennas at a receiving entity, a plurality of received symbol streams for a plurality of data symbol streams sent by a plurality of transmitting entities, one data symbol stream for each transmitting entity;
evaluating each of a plurality of sets of transmitting entities for possible transmission based on a metric and steering vectors for the transmitting entities in the set; and
selecting a set of transmitting entities with a highest metric value for transmission, wherein the selected set of transmitting entities comprises the plurality of transmitting entities,
wherein the data symbol stream for each transmitting entity is spatially processed with a steering vector derived independently for the transmitting entity and is sent from a plurality of transmit antennas at the transmitting entity, and wherein the plurality of data symbol streams are transmitted simultaneously by the plurality of transmitting entities.
2. The method of claim 1, further comprising:
processing the plurality of received symbol streams in accordance with a receiver spatial processing technique to obtain a plurality of recovered data symbol streams, which are estimates of the plurality of data symbol streams.
3. The method of claim 1, wherein the steering vector for each transmitting entity is derived based on a channel estimate for a wireless channel for the transmitting entity.
4. The method of claim 1, wherein the steering vector for each transmitting entity is derived by
decomposing a channel response matrix for the transmitting entity to obtain a plurality of eigenvectors and a plurality of singular values, and
forming the steering vector for the transmitting entity based on an eigenvector corresponding to a largest singular value among the plurality of singular values.
5. (canceled)
6. An apparatus at a receiving entity in a multiple-input multiple-output (MIMO) communication system, comprising:
a plurality of receiver units operative to obtain from a plurality of receive antennas a plurality of received symbol streams for a plurality of data symbol streams sent by a plurality of transmitting entities, one data symbol stream for each transmitting entity;
an evaluation unit operative to evaluate each of a plurality of sets of transmitting entities for possible transmission based on a metric and steering vectors for the transmitting entities in the set; and
a selection unit operative to select a set of transmitting entities with a highest metric value for transmission, wherein the selected set of transmitting entities comprises the plurality of transmitting entities;
wherein the data symbol stream for each transmitting entity is spatially processed with a steering vector derived independently for the transmitting entity and is sent from a plurality of transmit antennas at the transmitting entity, and wherein the plurality of data symbol streams are transmitted simultaneously by the plurality of transmitting entities.
7. The apparatus of claim 6, further comprising:
a receive spatial processor operative to process the plurality of received symbol streams in accordance with a receiver spatial processing technique to obtain a plurality of recovered data symbol streams, which are estimates of the plurality of data symbol streams.
8. The apparatus of claim 6, wherein the steering vector for each transmitting entity is derived based on a channel estimate for a wireless channel for the transmitting entity.
9. The apparatus of claim 6, wherein the steering vector for each transmitting entity is derived by
decomposing a channel response matrix for the transmitting entity to obtain a plurality of eigenvectors and a plurality of singular values, and
forming the steering vector for the transmitting entity based on an eigenvector corresponding to a largest singular value among the plurality of singular values.
10. (canceled)
11. An apparatus for receiving data in a multiple-input multiple-output (MIMO) communication system, comprising:
means for obtaining, from a plurality of receive antennas at a receiving entity, a plurality of received symbol streams for a plurality of data symbol streams sent by a plurality of transmitting entities, one data symbol stream for each transmitting entity;
means for evaluating each of a plurality of sets of transmitting entities for possible transmission based on a metric and steering vectors for the transmitting entities in the set; and
means for selecting a set of transmitting entities with a highest metric value for transmission, wherein the selected set of transmitting entities comprises the plurality of transmitting entities,
wherein the data symbol stream for each transmitting entity is spatially processed with a steering vector derived independently for the transmitting entity and is sent from a plurality of transmit antennas at the transmitting entity, and wherein the plurality of data symbol streams are transmitted simultaneously by the plurality of transmitting entities.
12. The apparatus of claim 11, further comprising:
means for processing the plurality of received symbol streams in accordance with a receiver spatial processing technique to obtain a plurality of recovered data symbol streams, which are estimates of the plurality of data symbol streams.
13. The apparatus of claim 11, wherein the steering vector for each transmitting entity is derived based on a channel estimate for a wireless channel for the transmitting entity.
14. The apparatus of claim 11, wherein the steering vector for each transmitting entity is derived by
decomposing a channel response matrix for the transmitting entity to obtain a plurality of eigenvectors and a plurality of singular values, and
forming the steering vector for the transmitting entity based on an eigenvector corresponding to a largest singular value among the plurality of singular values.
15. (canceled)
16. A computer-program product for receiving data in a multiple-input multiple-output (MIMO) communication system comprising a computer readable medium having instructions thereon, the instructions comprising:
code for obtaining, from a plurality of receive antennas at a receiving entity, a plurality of received symbol streams for a plurality of data symbol streams sent by a plurality of transmitting entities, one data symbol stream for each transmitting entity;
code for evaluating each of a plurality of sets of transmitting entities for possible transmission based on a metric and steering vectors for the transmitting entities in the set; and
code for selecting a set of transmitting entities with a highest metric value for transmission, wherein the selected set of transmitting entities comprises the plurality of transmitting entities,
wherein the data symbol stream for each transmitting entity is spatially processed with a steering vector derived independently for the transmitting entity and is sent from a plurality of transmit antennas at the transmitting entity, and wherein the plurality of data symbol streams are transmitted simultaneously by the plurality of transmitting entities.
17. The computer-program product of claim 16, further comprising:
code for processing the plurality of received symbol streams in accordance with a receiver spatial processing technique to obtain a plurality of recovered data symbol streams, which are estimates of the plurality of data symbol streams.
18. The computer-program product of claim 16, wherein the steering vector for each transmitting entity is derived based on a channel estimate for a wireless channel for the transmitting entity.
19. The computer-program product of claim 16, wherein the steering vector for each transmitting entity is derived by
decomposing a channel response matrix for the transmitting entity to obtain a plurality of eigenvectors and a plurality of singular values, and
forming the steering vector for the transmitting entity based on an eigenvector corresponding to a largest singular value among the plurality of singular values.
20. (canceled)